Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study

BACKGROUND: A paradigm shift has occurred in cancer chemotherapy from tumor‐specific treatment with cytotoxic agents to personalized medicine with molecular‐targeted drugs. Thus, it is essential to identify genomic alterations and molecular features to recommend effective targeted molecular medicine...

Descripción completa

Detalles Bibliográficos
Autores principales: Shirota, Hidekazu, Komine, Keigo, Takahashi, Masanobu, Takahashi, Shin, Miyauchi, Eisaku, Niizuma, Hidetaka, Tada, Hiroshi, Shimada, Muneaki, Niihori, Tetsuya, Aoki, Yoko, Sugiyama, Ikuko, Kawamura, Maako, Yasuda, Jun, Suzuki, Shuhei, Iwaya, Takeshi, Saito, Motonobu, Saito, Tsuyoshi, Shibata, Hiroyuki, Furukawa, Toru, Ishioka, Chikashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028111/
https://www.ncbi.nlm.nih.gov/pubmed/36251535
http://dx.doi.org/10.1002/cam4.5349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028111/
https://www.ncbi.nlm.nih.gov/pubmed/36251535
http://dx.doi.org/10.1002/cam4.5349

Ejemplares similares